Rate Video

ASCO 2015 | Design and results of pacritinib for myelofibrosis trial (PERSIST-1)

Jean-Jacques Kiladjian • 2 Jun 2015

ASCO 2015

Myeloproliferative Neoplasms Pacritinib

PERSIST-1

Dr Jean-Jacques Kiladjian, at the 2015 American Society of Clinical Oncology (ASCO), describes the design and recent results of the PERSIST- 1 trial of pacritinib for patients with myelofibrosis, with specific focus on the impact on thrombocytopenia, low-platelet count, and transfusion independence.

IMbark study: imetelstat in R/R triple-negative myelofibrosis

Jean-Jacques Kiladjian • 11 Dec 2020

RUXOPEG: a promising novel combination for MPN-associated myelofibrosis

Jean-Jacques Kiladjian • 3 Dec 2018

Characteristics and outcomes of young patients with MPNs

Jean-Jacques Kiladjian • 16 May 2022

Agents of interest being explored in essential thrombocythemia and polycythemia vera

Jean-Jacques Kiladjian • 22 Aug 2022

Related Videos

Allo-HSCT in BCR-ABL-negative MPN pretreated with JAK inhibitors

Key updates in MPNs from ASH 2018

Claire Harrison

KRT‑232: first-in-class MDM2I for myelofibrosis R/R to JAK inhibitor therapy

Haifa Kathrin Al-Ali

Rapid responses with targeted agent in Phase I trial for systemic mastocytosis

Daniel DeAngelo